oa Journal of Endocrinology, Metabolism and Diabetes in South Africa - Setting glycaemic targets in patients with type 2 diabetes. Where to now? : guest editorial
Results from several randomised controlled trials have demonstrated conclusively that microvascular complications can be reduced in patients with both type 1 and type 2 diabetes. These trials have indicated that an HbA1c level ≤ 7% is a reasonable target to aim for if attempts are to be made to reduce or delay the advent of microvascular complications. This target has therefore been incorporated into the American Diabetes Association (ADA), and subsequently the Society for Endocrinology, Metabolism and Diabetes of South Africa (SEMDSA) guidelines. However, cardiovascular disease (CVD) remains the leading cause of both morbidity and mortality in patients with type 2 diabetes and over 65% of deaths in these patients are attributable to heart disease or stroke. Given the known increasing prevalence of type 2 diabetes globally, the CVD burden due to these conditions is expected to continue rising. It is therefore important to understand the relationship between improved glucose control and the occurrence of macrovascular disease.
Article metrics loading...